The approval is based on the results of the pivotal Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) among participants treated with setmelanotide. Specifically, patients receiving the therapy achieved a -15.8% reduction in BMI compared to a +2.6% increase in the placebo group over a 52-week period. The trial included 142 patients, and setmelanotide was generally well tolerated, with the most common treatment-emergent adverse events being skin hyperpigmentation, nausea, vomiting, and headache.
With this expanded indication, IMCIVREE is now indicated for adults and pediatric patients aged 4 years and older with acquired HO, providing a long-awaited treatment option for a patient population that previously had no approved therapies. The company plans to make IMCIVREE available immediately to patients in the U.S. and is committed to supporting access through its Rhythm InTune program, which offers personalized educational support and assistance with insurance navigation.
David Meeker, M.D., Chairman and CEO of Rhythm, emphasized the transformative nature of this approval, stating, "IMCIVREE is now the first and only FDA-approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options."
The approval of IMCIVREE is expected to have a significant impact on the company's growth trajectory, as it opens up a new market for Rhythm Pharmaceuticals. The company estimates that there are approximately 10,000 individuals living with acquired HO in the U.S., highlighting the potential for substantial patient engagement and revenue generation.
In conclusion, the FDA's approval of IMCIVREE for acquired hypothalamic obesity represents a major advancement in the treatment of this rare condition, providing hope and a path forward for patients and their families. Rhythm Pharmaceuticals is poised to capitalize on this opportunity as it continues to develop innovative therapies for rare neuroendocrine diseases.
